🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Myeloma Paper of the Day: Report of a modified Staging System for #Waldenström macroglobulinemia utilizing age, albumin, and LDH that provides a simple, clinically useful, and externally validated prognostic model that reliably predicts prognosis: pubmed.ncbi.nlm.nih.gov/38788183/.

Impressive data w BTK degrader NX-5948 in R/R CLL. ORR 70% in double-ref CLL, regardless of BTK mut. Great durability and safety

After an incredible journey Georgia Cancer Center, I am starting a new chapter as a lymphoma attending at MD Anderson Cancer Center Grateful to my phenomenal mentor Jorge Cortes MD for his support and guidance. Looking forward to new beginnings and working with #lymsm stalwarts! #endcancer

Energizing talk from Dr. Jeremy Abramson breaking down pros and cons of Pola-R-CHP The essential points of this talk apply to any new cancer therapy providing benefit over SOC (e.g. improved PFS, lower toxicity, etc) WITHOUT improved OS Quality of OS counts!!

Hugely important trial results in Journal of Clinical Oncology Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

MD Anderson Cancer Center’s #Lymphoma-#Myeloma Fellowship Program. Contact Program Coordinator: Lisa Foucheaux-Heider ([email protected]; 713-745-4247).

Speaking of...46 pts with Bing-Neel in UK series #ASH24: - 1-yr PFS after 1L HD-MTX 81% - 1-yr PFS after 1L BTKi (mostly zanu) 100% - 3-yr PFS after 2L BTKi (mostly ibru) 89% - Achieving CSF negativity = no subsequent relapse BTKi efficacious for BNS & preferred over MTX. #lymsm

Another election is ongoing & we need #healthcare advocacy more than ever- ASCO members - elect Jason Westin, MD FACP FASCO to Board of Directors. He is a tireless advocate (winner of 2024 ASCO Advocate of the Year Award) for oncology and will serve us well! society.asco.org/about-asco/asc…

PhasED-seq & relapse in cHL #ASH24 Ash Alizadeh, MD/PhD 🇺🇸: Early-stage: - MRD+ at C3D1➡️inferior PFS (despite iPET2 CMRs) - no pts who were iPET2+ but MRD- had POD Adv-stage: - MRD at EOT is best (vs C3 or C5) - HR 6.2 for PFS if EOT PET- but MRD+! Great data for adapted designs! #lymsm

In patients with Hodgkin lymphoma, when should you avoid using Bleomycin and how should you manage pulmonary toxicity? Aisling Barrett and Graham Collins provide an excellent Good Practice Paper with answers OncoAlert #lymsm onlinelibrary.wiley.com/doi/10.1111/bj…

B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma ow.ly/wWPF50U2zal #bloodwork #lymphoidneoplasia

15-yr F/U of my fav study by Ardeshna et al.: W&W v Rx4 low tumor burden FL - median TTNT: NR in R maint, 14.8 yrs (!!!) in Rx4, 5.6 yrs in W&W - 34% of W&W cohort with no tx at 15 yrs! - women: shorter TTNT w/ W&W & longer TTNT with R maint (biological diff?) 1/2 #lymsm

Glofit+pola for relapsed Burkitt lymphoma NEJM Curious, to say the least! nejm.org/doi/full/10.10… Mark Roschewski

Congratulations to Dr. Christopher Flowers, on receiving ASCO’s 2025 Jamie Von Roenn Excellence in Teaching and Mentorship Award. His leadership and dedication to training future oncology leaders continue to shape the field. Read more: spr.ly/6012NFyVs #EndCancer #ASCO25

Miss you all! Big congratulations to a great group of fellows!

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by David Russler-Germain, MD/PhD at #18icml International Conference on Malignant Lymphoma, now available online in Cancer Cell. #lmsm WashU Medicine MD Anderson Cancer Center. cell.com/cancer-cell/fu…

Together we lead, we learn, we lift each other up. Thank you to all who joined our WiL gathering at #18ICML — an inspiring evening filled with connection, purpose, and power. Let’s keep building this global community, one voice at a time. 🌍 #womeninhematology #ICML2025

RWE: Similar outcomes in older adults w bispecific treatment in LBCL with tolerable toxicity profile presented by Swetha Kambhampati for #CUBIC consortium #ICML2025 Ajay Major, MD, MBA City of Hope MD Anderson Cancer Center Women in Lymphoma - [email protected]

Passionate about #Hematology #HCT & #CellularTherapy? We’re opening new spots on The EBMT Trainee Committee!🌱 Apply now👉 forms.gle/rgMsEogFFxT6B3… 🗓 Deadline: Friday, 15 August Your perspective matters. Let’s grow together💥 Please spread the word!

🔈🔉🔊 Apply for European Hematology Association “Clinical Research Training in #Hematology” #CRTH This program provides early-career #researchers 👨‍⚕️👩‍🔬 with a unique, year-long training and #mentoring experience. 📆 Deadline for applications: September 2, 2025. ➕ℹ️: ehaweb.org/education-trai…